Ardelyx forecasts combined 2026 revenue from IBSRELA and XPHOZAH to exceed $500 million, with IBSRELA at $410–430 million and XPHOZAH at $110–120 million. The company reiterated targets of $1 billion IBSRELA sales by 2029 and $750 million peak for XPHOZAH, while guiding 2026 operating expenses up to $520 million.
Ardelyx forecasts combined 2026 revenue from IBSRELA and XPHOZAH to exceed $500 million, with IBSRELA contributing $410–430 million and XPHOZAH $110–120 million to the total.
The company outlined four priorities for 2026, including growing IBSRELA demand and maintaining XPHOZAH momentum, and guided operating expenses up to $520 million driven by a sales force expansion from 124 to 144 representatives and enhanced patient-activation programs.
Ardelyx’s late-stage trial of IBSRELA in chronic idiopathic constipation remains on schedule for full enrollment by year-end, with top-line data expected in mid-2027, representing a key pipeline catalyst.
Management reiterated a $1 billion sales target for IBSRELA by 2029 and a $750 million peak for XPHOZAH, while emphasizing that profitability is expected in the near term once top-line results provide further clarity.
